Company intelligence / Profile preview

Carrick Therapeutics

Boston, Massachusetts, United Statescarricktherapeutics.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company has two significant programs in clinical studies: CT7001 (oral CDK7 inhibitor) progressing through phase 1 studies, and CT900 which has shown clinical proof-of-concept in platinum-resistant ovarian cancer[5]

Therapeutic areas: Oncology
Modalities: Small molecules (CDK7 inhibitor, Folate Receptor Alpha targeted therapy)
Industry: Biotech

Drug pipeline

3 assets

samuraciclib

2 more assets in the full pipeline.

Request access →

Partnerships

Network of Pharma partners, clinicians, scientists, leading research institutes and hospitals[1]

Beyond the preview

Go deeper on Carrick Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carrick Therapeutics.

Explore the full profile